5.140USD+0.59%Mkt Cap: 400.46M USDP/E: —Last update: 2026-05-26
Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States. Its product pipeline comprises LX2006, an AAVrh10-based gene the…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
105.81BDKKP/E 20.4
66.47BUSDP/E 15.5
46.56BEURP/E 30.5
43.89BEURP/E 36.5
39.41BUSDP/E 74.0
32.84BUSD—
32.05BSEKP/E 47.4
Indicators:|
Key Statistics
Company
Market Cap400.46M USD
Enterprise Value224.99M USD
Revenue (TTM)—
Gross Profit-62.33M USD
Net Income (TTM)-99.96M USD
Revenue/Share—
Last Price5.140 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees59
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-4.27
PEG—
EV/EBITDA-2.31
EV/Revenue—
P/S—
P/B1.67
EPS (TTM)-1.12
EPS (Forward)-1.22
52W Range
2.51131% of range10.99
52W High10.99 USD
52W Low2.511 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-40.52%
ROA-37.20%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-98.56M USD
CapEx (TTM)397.00K USD
FCF Margin—
FCF Yield-16.82%
Net Debt-185.68M USD
Net Debt/EBITDA1.91
Balance Sheet
Debt/Equity0.03
Current Ratio14.16
Quick Ratio13.61
Book Value/Sh3.125 USD
Cash/Share2.458 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.2 (Strong Buy)
Target (Mean)19.64 USD
Target Range10.00 USD – 30.00 USD
# Analysts11
Ownership
Shares Out.78.52M
Float47.53M
Insiders0.55%
Institutions115.44%
Short Interest
Short Ratio13.2d
Short % Float19.56%
Short % Out.16.64%
Shares Short13.07M
Short (prev mo.)12.50M
Technical
SMA 505.898 (-12.9%)
SMA 2007.151 (-28.1%)
Beta1.53
S&P 52W Chg28.31%
Avg Vol (30d)736.26K
Avg Vol (10d)981.85K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—